A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs

NCT06020144 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: TLL-018
DRUG: Tofacitinib

Sponsor

Hangzhou Highlightll Pharmaceutical Co., Ltd